PKC 412;Le PKC 412

Bulletin du Cancer

Volumn 86, Issue 7-8, 1999, Pages 614-617

  Lansiaux, Amélie ^a   Fabbro, Doriano ^b   Meyer, Thomas ^b   Hamy, François ^b   Bailly, Christian ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; FLUOROURACIL; MIDOSTAURIN; MITOGEN ACTIVATED PROTEIN KINASE; PACLITAXEL; PROTEIN KINASE C INHIBITOR; STAUROSPORINE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; NONHUMAN; PHOSPHORYLATION; REVIEW;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; ENDOTHELIAL GROWTH FACTORS; ENZYME INHIBITORS; HUMANS; LYMPHOKINES; PROTEIN KINASE C; SIGNAL TRANSDUCTION; STAUROSPORINE; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0032829936     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. 1. Caravatti G, Meyer T, Fredenhagen A, Trinks U, Kump W, Mett H, Fabbro D. Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C. Biorg Med Chem Lett 1994 ; 4 : 399-404.
2. 2. Blobe GC, Obeid LM, Hannun YA. Regulation of protein kinase C and role in cancer biology. Cancer Metastasis Rev 1994 ; 13 : 411-31.
3. 3. Perletti GP, Monti E. PKCs: transducers of critical signals in cancer cells (review). Int J Oncol 1996 ; 9 : 171-7.
4. 4. Andrejauskas-Buchdunger E, Regenass U. Differential inhibition of the epidermal growth factor-, platelet-derived growth factor-, and protein kinase C mediated signal transduction pathways by the staurosporine derivative CGP 41251. Cancer Res 1992 ; 52 : 5353-8.
5. 5. Lawrence DS, Niu J. Protein kinase inhibitors: the tyrosine-specific kinases. Pharmacol Ther 1998 ; 77 : 81-114.
6. 6. Meyer T, Regenass U, Fabbro D, Alteri E, Rösel J, Müller M, Caravatti G, Matter A. A derivative of staurosporine (CGP 41251) shows selectivity for protein kinase C inhibition and in vitro antiproliferative as well as in vivo antitumour activity. Int J Cancer 1989 ; 43 : 851-6.
7. 7. Plate KH, Breier G, Millauer B, Ullrich A, Risau W. Up-regulation of vascular endothelial growth factor and its cognate receptors in a rat glioma model of tumor angiogenesis. Cancer Res 1993 ; 53 : 5822-7.
8. 8. Begemann M, Kashimawo SA, Heitjan DF, Schiff PB, Bruce JN, Weinstein B. Treatment of human glioblastoma cells with the staurosporine derivative CGP 41251 inhibits cdc2 and ckd2 kinase activity and increases radiation sensitivity. Anticancer Res 1998 ; 18 : 2275-82.
9. 9. Akiyama T, Shimizu M, Okabe M, Tamaoki T, Akinaga S. Differential effects of UCN-01 and PKC 412 on cell cycle progression and cdc2/cyclin B1 regulation in A341 cells synchronized at M phase by nocodazole. Anticancer Drugs 1999 ; 10 : 67-78.
10. 10. Begemann M, Kashimawo SA, Choi YA, Kim S, Christiansen KM, Duigou G, et al. Inhibition of the growth of glioblastoma by CGP 41251, an inhibitor of protein kinase C and by a phorbol ester tumor promoter. Clin Cancer Res 1996 ; 2 : 1017-30.
11. 11. Ikegami Y, Yano S, Nakao K. Effects of the new selective protein kinase C inhibitor 4′-N-benzoyl staurosporine on cell cycle distribution and growth inhibition in human small cell lung cancer cells. Arzneim-Forsch/Drug Res 1996 ; 46 : 201-4.
12. 12. Sedlak J, Hunakova L, Dutaj J, Chorvath B, Novotny L. Effects of protein kinase C inhibitor, staurosporine derivative CGP 41251, on cell cycle, DNA synthesis and drug uptake in neoplastic cell lines. Anticancer Drugs 1995 ; 6 : 70-6.
13. 13. Blobe GC, Sachs CW, Khan WA, Fabbro D, Stabel S, Wetsel W, et al. Selective regulation of protein kinase C (PKC) isoenzymes in multidrug-resistant MCP-7 cells. J Biol Chem 1993 ; 268 : 658-64.
14. 14. Beltram JP, Fan D, Fidler IJ, O'Brian AC. Chemosensitization of cancer cells by the staurosporine derivative CGP 41251 in association with decreased P-glycoprotein phosphorylation. Biochem Pharmacol 1997 ; 53 : 245-7.
15. 15. Sampson E, Wolff CL, Abraham I. Staurosporine reduces P-glycoprotein expression and modulates MDR. Cancer Lett 1993 ; 68 : 7-14.
16. 16. Utz I, Hofer S, Regenass U, Hilbe W, Thaler J, Grunicke H, Hofmann J. The protein kinase C inhibitor CGP 41251, a staurosporine derivative with antitumor activity, reverses multidrug resistance. Int J Cancer 1994 ; 57 : 104-10.
17. 17. Utz I, Spitaler M, Rybczynska M, Ludescher C, Hilbe W, Regenass U, et al. Reversal of multidrug resistance by the staurosporine derivatives CGP 41251 and CGP 42700. Int J Cancer 1998 ; 77 : 64-9.
18. 18. Gekeler V, Boer R, Uberall F, Ise W, Schubert C, Utz I, et al. Effects of the selective bisindolylmaleimide protein kinase C inhibitor GF 109203X on P-glycoprotein-mediated multidrug resistance. Br J Cancer 1996 ; 74 : 897-905.
19. 1-acid glycoprotein. Cancer Res 1998 ; 58 : 3248-53.
20. 20. Ludescher C, Eisterer W, Hilbe W, Hofmann J, Thaler J. Decreased potency of MDR-modulators under serum conditions determined by functional assay. Br J Haematol 1995 ; 91 : 652-7.
21. 21. Killion JJ, Beltran P, O'Brian CA, Yoon SS, Fan D, Wilson MR, Fidler IJ. The antitumor activity of doxorubicin against drug-resistant murine carcinoma is enhanced by oral administration of a synthetic staurosporine analogue, CGP 41251. Oncol Res 1995 ; 7 : 453-9.
22. 22. McDonald AC, Propper D, King D. Phase I and pharmacokinetic study of CGP 41251, an inhibitor of protein kinase C. Ann Oncol 1998 ; 9 : 212, A742.
23. 23. Propper D, McDonald A, Thavasu P, Balkwill F, Caponigro F, Yap A, et al. Phase I study of the protein kinase C inhibitor CGP 41251: tolerability and effects on signal transduction ex vivo. Ann Oncol 1998 ; 9 : 112, A428.
24. 24. Czendlik C, Graf P. Safety tolerability and pharmacokinetics of CGP 41251, a protein kinase C inhibitor (phase I study). Ann Oncol 1996 ; 7 : 77, A264.
25. 25. Gescher A. Analogs of staurosporine : potential anticancer drugs. Biochem Pharmacol 1998 ; 31 : 721-8.